<DOC>
	<DOCNO>NCT02476708</DOCNO>
	<brief_summary>This 8-week randomized , double-blind , placebo-controlled , parallel , fixed-dose pilot clinical trial curcumin treatment cognitive impairment schizophrenia.The primary aim pilot trial provide effect size estimate efficacy curcumin improve cognitive functioning schizophrenia . Secondary goal determine effect curcumin time negative positive symptom , association inflammatory marker .</brief_summary>
	<brief_title>A Pilot Trial Curcumin Effects Cognition Schizophrenia</brief_title>
	<detailed_description>This 8-week randomized , double-blind , placebo-controlled , parallel , fixed-dose pilot clinical trial curcumin treatment cognitive impairment schizophrenia . Cognitive impairment persistent negative symptom core dimension schizophrenia ; however current antipsychotic treatment fail address issue . Evidence suggest cognitive impairment limit patient late-stage schizophrenia . High rate cognitive impairment patient first episode psychosis indicate cognitive impairment solely consequence long-term antipsychotic treatment , rather endure problem course schizophrenia . Likewise , negative symptom persist throughout entire course , associate poor overall functioning . Currently , pharmacological agent specifically aim treat cognitive functioning persistent negative symptom ; therefore , grow interest development effective treatment unmet need . The primary aim pilot trial provide effect size estimate efficacy curcumin improve cognitive functioning schizophrenia . Secondary goal determine effect curcumin time negative positive symptom , association inflammatory marker . Eligible participant randomize curcumin ( n=20 ) placebo ( n=20 ) 1:1 ratio . A commercially available surface-controlled water soluble form 600mg curcumin ( 10 % formulation ) match placebo capsule administer three time day total 8 week .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Curcumin</mesh_term>
	<criteria>Inclusion criterion : 1 . 18 65 year age 2 . English speak 3 . Diagnostic Statistical Manual IV diagnosis schizophrenia schizoaffective disorder base Structured Clinical Interview Diagnostic Statistical ManualIV ( SCID ) 4 . Symptomatic stability confirm clinical staff 8 week prior study 5 . No change antipsychotic medication within last 8 week 6 . No change antipsychotic dose last 4 week . Exclusion criterion : 1 . Unable provide inform consent 2 . Diagnostic Statistical ManualIV ( DSMIV ) diagnosis alcohol/substance dependence 3 . Recent history gastrointestinal bleeding ulceration 4 . Recent history gallstone and/or bile duct obstruction 5 . Significant uncontrolled systemic illness ( e.g . chronic renal failure , chronic liver disease , poorly control diabetes , poorly control congestive heart failure , chronic infectious disease , chronic autoimmune disease ) 6 . Known intolerance turmeric , curcumin , curry 7 . Pregnancy breastfeed 8 . Current use antiplatelet , anticoagulant , glucocorticoid , immunosuppressants 9 . Daily use nonsteroidal antiinflammatory use .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>schizophrenia</keyword>
	<keyword>schizoaffective disorder</keyword>
	<keyword>cognition</keyword>
	<keyword>curcumin</keyword>
</DOC>